Portuguese company CANNPRISMA has received an authorisation licence for the cultivation, import and export of medical cannabis products.
Medical cannabis product producer CANNPRISMA has received its licence from the Polícia de Segurança Pública (PSP – Public Security Police) and INFARMED to cultivate, process, import and export cannabis-based products for medicinal use.
The authorisation followed an on-site inspection by both PSP and INFARMED, the Portuguese government agency responsible to the Ministry of Health, which evaluates, authorises, regulates and controls medicines for human use, and following publication in Diário da República.
Medical cannabis product production
The 10 hectares cultivation and processing unit of CANNPRISMA, located in Castro Marim, includes around 3000 square metres of greenhouses and support infrastructure which utilises the latest technology, respecting all the required quality standards and following all GMP requirements.
COVID-19 delayed the process of obtaining the definitive licence, however, it has now been concluded following the successful on-site inspection. The licence means that the entire activity of the company from Algarve complies with the Good Agricultural and Collection Practices (GACP). The licensing has already been subject to inspection by PSP, which confirmed compliance with all safety rules in accordance with current legislation.
CANNPRISMA says that the construction of the factory is expected to be completed by the end of 2021, as well as its authorisation for GMP operation by INFARMED, and that the GMP manufacturing facilities, installed in Vila Real de Santo António, already has an aptitude decision from INFARMED.
CANNPRISMA CEO, João Nascimento, said: “Obtaining this authorisation is in line with CANNPRISMA’s vertical strategy in the Medicinal Cannabis business area for the pharmaceutical industry – R&D, cultivation and harvesting, drying and processing, extraction, crystallisation API, drug manufacturing, packaging and labelling.
“In other words, we want this activity to cover the entire chain of value from R&D, cultivation, transformation and placing on the market of cannabis-based products for medicinal purposes.
“This project started in 2018, with a team with a lot of experience in the pharmaceutical industry and in agriculture and it is thanks to them that we achieved this milestone.”
The company says there is great potential for Portugal to become a leading country in research, production and one of the largest exporters of medicinal cannabis in Europe.
[activecampaign form=31]
